Advances in the field of tumor immunotherapy have given great hope for those treating cancer. We are in an era of unprecedented achievements, as evidenced by impressive clinical responses in patients treated with adoptive cell therapy and immune checkpoint inhibitors.
For more than a year before her stage 4 lung cancer was found, 35-year-old Alisa Secaida, a never-smoker and a physically active Southern Californian, had been experiencing a persistent cough and, increasingly, fatigue.
